ClinicalTrials.gg
CompletedNCT04850339Updated May 16, 2022

First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers

A Phase 1 interventional study of ANXV and Placebo in Healthy, sponsored by Annexin Pharmaceuticals AB. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-16.

Sponsored by Annexin Pharmaceuticals AB · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is an adaptive, randomised, double-blind, single-centre, placebo-controlled phase I, First in Human study designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous dosing of ANXV in healthy male subjects.

Read the detailed description

This First in Human study is divided in two parts. Part I, Single Ascending Dose (SAD), will explore safety, tolerability and PK of single intravenous doses of ANXV. Part II, Multiple Ascending Dose (MAD), will explore safety, tolerability and PK of multiple doses (five consecutive daily doses) of intravenous ANXV.

The objectives of this study are:

Primary objective:

  • To evaluate the safety and tolerability of single/multiple ascending doses of ANXV in healthy male subjects.

Secondary objective:

  • To determine the PK profile of single/multiple ascending doses of ANXV in healthy male subjects.

Exploratory objectives:

  • To evaluate ADA to ANXV and other relevant parameters.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Annexin Pharmaceuticals AB is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written for participation in the study.
  2. Healthy male subject aged 18-50 years inclusive at screening.
  3. ≥ 18.0 and ≤ 30.0 kg/m2 and weight at least 50 kg and no more than 100 kg at screening.
  4. Overtly healthy based on medical history, physical findings, vital signs, and laboratory values at the time of screening, as judged by the Investigator.
  5. Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner, and refrain from donating sperm from the date of dosing until 3 months after (last) dosing with the IMP. Their female partner of are expected to use methods with a failure rate of \< 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD] or intrauterine hormone-releasing system [IUS]).

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  2. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  3. within the past 5 years with the exception of in situ removal of basal cell carcinoma.
  4. Any planned major surgery within the duration of the study.
  5. Any positive result on screening for serum surface antigen (HbsAg), antibody and (HIV).
  6. History of thromboembolic events.
  7. History of significant bleeding (gross haematuria, haemoptysis, gastrointestinal tract bleeding).
  8. Evidence or history of a hypercoagulable state (e.g. shortened ).
  9. Prior exposure to recombinant Annexin A5 (for diagnostic purposes).
  10. Any history of coronary artery disease or cerebrovascular accident.
  11. Known cardiac disease, cardiac anomaly or cardiac deformity.
  12. Known heredity for disease with described presence of potentially pathogenic Annexin A5 antibodies, e.g. antiphospholipid syndrome, systemic lupus erythematosus or systemic sclerosis, as judged by the Investigator.
  13. Any history of or active peptic ulcer disease.
  14. Any clinically significant disease affecting the respiratory tract (e.g. obstructive and restrictive respiratory disease, chronic respiratory disease such as alveolitis, inflammatory respiratory disease, autoimmune respiratory disease, present respiratory infections, pulmonary vascular disease) that would influence the results of the study or the subject's ability to participate in the study, as judged by the Investigator.
  15. (based on plasma-creatinine) outside of normal range at screening or known renal impairment (≤70 mL/min).
  16. Vaccination with within 4 weeks of the screening visit.
  17. After 5 minutes supine rest at the time of screening, any vital signs values outside the following ranges:

    • Systolic blood pressure \<90 or >140 mmHg, or
    • Diastolic blood pressure \<40 or >90 mmHg, or
    • Pulse \<40 or >100 bpm
  18. Current evidence or history of bacterial, viral or fungal infections within 7 days before (first) IMP administration as judged by the Investigator.
  19. Prolonged (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting at the time of screening, as judged by the Investigator.
  20. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to ANXV.
  21. Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals within two weeks prior to the (first) administration of IMP, except occasional intake of paracetamol (maximum 2,000 mg/day; and not exceeding 3,000 mg/week), at the discretion of the Investigator and nasal decongestants without cortisone, antihistamine or anticholinergics for a maximum of 10 days, at the discretion of the Investigator.
  22. Planned treatment or treatment with another drug within 3 months prior to Day -1. Subjects consented and screened but not dosed in previous phase I studies are not excluded.
  23. Current smokers or users of nicotine products. Smokers that stopped smoking \<3 months prior to screening.
  24. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to administration of the IMP.
  25. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
  26. Presence or history of drug abuse, as judged by the Investigator.
  27. History of, or current use of, anabolic steroids.
  28. Excessive caffeine consumption defined by a daily intake of >5 cups of caffeine containing beverages.
  29. Intake of xanthine and/or taurine containing energy drinks within 2 days prior to screening.
  30. Plasma donation within one month of screening or blood donation (or corresponding blood loss) of >450 ml during the three months prior to screening.
  31. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements, or unfit for participation for any other reason.
  32. Previous confirmed COVID-19 disease requiring hospital care or positive COVID-19 test on admission to the clinic.
  33. Insufficient venous access for study procedures.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    ANXV single dose

    ANXV in a single ascending dose pattern in four dose levels.

    Biological: ANXV

  • Placebo comparator
    Placebo single dose

    Placebo in a single ascending dose pattern in four dose levels.

    Other: Placebo

  • Active comparator
    ANXV multiple dose

    ANXV in a multiple ascending dose pattern in three dose levels.

    Biological: ANXV

  • Placebo comparator
    Placebo multiple dose

    Placebo in a multiple ascending dose pattern in four dose levels.

    Other: Placebo

Interventions

  • BiologicalANXV

    Intravenous infusion

  • OtherPlacebo

    Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Frequency of adverse events.

    Frequency of adverse events at single and multiple ascending doses of ANXV.

    Time frame: From day 1 (inclusion) until day 35

  2. Seriousness of adverse events.

    Seriousness of adverse events at single and multiple ascending doses of ANXV.

    Time frame: From day 1 (inclusion) until day 35

  3. Intensity of adverse events.

    Intensity of adverse events at single and multiple ascending doses of ANXV.

    Time frame: From day 1 (inclusion) until day 35

Secondary outcomes

  1. PK profile of single and multiple ascending doses of ANXV: AUClast

    AUC from time zero to time of last quantifiable analyte concentration (AUClast)

    Time frame: 0-24hours after IMP administration

  2. PK profile of single and multiple ascending doses of ANXV: Cmax

    Observed maximum concentration (Cmax)

    Time frame: 0-24hours after IMP administration

  3. PK profile of single and multiple ascending doses of ANXV: Tmax

    Time to Cmax (Tmax)

    Time frame: 0-24hours after IMP administration

  4. PK profile of single and multiple ascending doses of ANXV: λz

    Terminal slope of a semi-logarithmic concentration-time curve (λz)

    Time frame: 0-24hours after IMP administration

  5. PK profile of single and multiple ascending doses of ANXV: T½

    Terminal half life (T½)

    Time frame: 0-24hours after IMP administration

  6. PK profile of single and multiple ascending doses of ANXV: CL

    Clearance (CL)

    Time frame: 0-24hours after IMP administration

  7. PK profile of single and multiple ascending doses of ANXV: Vz

    Volume of distribution (Vz)

    Time frame: 0-24hours after IMP administration

  8. PK profile of single and multiple ascending doses of ANXV: Fraction excreted in urine (fe)

    Fraction excreted in urine (fe)

    Time frame: 0-24hours after IMP administration

07

Study locations

1 site
  • QPS Netherlands B.V.
    Groningen, 9713, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Oct 2021, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2021
First posted
Apr 20, 2021
StartActual
Dec 21, 2020
Primary completionActual
Oct 27, 2021
CompletionActual
Oct 27, 2021
Last update
May 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04850339
Lead sponsor
Annexin Pharmaceuticals AB
Responsible party
Sponsor
First posted
Apr 20, 2021
Start date
Dec 21, 2020
Primary completion
Oct 27, 2021
Completion
Oct 27, 2021
Last update
May 16, 2022

Study contacts

Anna Frostegård, MD, PhD
study director · Annexin Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion